A Physical Link between the Pseudorabies Virus Capsid and the Nuclear Egress Complex

Mindy Leelawong, Dongsheng Guo, and Gregory A. Smith *

Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611

Received 6 July 2011/Accepted 25 August 2011

Following their assembly, herpesvirus capsids exit the nucleus by budding at the inner nuclear membrane. Two highly conserved viral proteins are required for this process, pUL31 and pUL34. In this report, we demonstrate that the pUL31 component of the pseudorabies virus nuclear egress complex is a conditional capsid-binding protein that is unmasked in the absence of pUL34. The interaction between pUL31 and capsids was confirmed through fluorescence microscopy and Western blot analysis of purified intranuclear capsids. Three viral proteins were tested for their abilities to mediate the pUL31-capsid interaction: the minor capsid protein pUL25, the portal protein pUL6, and the terminase subunit pUL33. Despite the requirement for each protein in nuclear egress, none of these viral proteins were required for the pUL31-capsid interaction. These findings provide the first formal evidence that a herpesvirus nuclear egress complex interacts with capsids and have implications for how DNA-containing capsids are selectively targeted for nuclear egress.

Although the herpesviridae constitute a diverse array of viral agents, all share a related structure that begins as an icosahedral protein shell that is assembled and packaged with a linear double-stranded DNA (dsDNA) genome in the nucleus of the host cell. Capsid assembly and genome encapsidation are complex processes with a reasonably high failure rate; defective capsid species are readily purified from infected cells in culture and are visible in electron micrographs of infected cells and tissues. The modest fidelity of these processes appears to be compensated for by a quality control step operating at the nuclear membrane that selects capsids containing genomes for egress from the nucleus to the cytosol (16, 65, 79, 87). Viral proteins resident in the inner nuclear membrane constitute a nuclear egress complex (NEC). How the NEC selects for packaged capsids is not understood, and in fact, interactions between the capsid and NEC remain to be defined.

Herpesvirus assembly begins with the formation of fragile procapsid icosahedral shells that are built upon protein scaffolds (15, 51, 53, 68, 83). The encapsidation of the viral genome occurs through a dodecameric portal ring that occupies one of the 12 vertices of the procapsid shell and is encoded by the UL6 gene (11, 12, 19, 52, 84). The terminase complex, consisting of the products of the UL15, UL28, and UL33 genes, is the molecular motor that facilitates the packaging of the genome through the portal (2, 8, 60, 90, 94). The initial stabilization of the capsid occurs concomitantly with the cleavage of the internal scaffolding by the VP24 protease (32), with additional structural rigidity gained at a subsequent step that may be coincident with the release of the proteolyzed scaffold and genome packaging (70). From the progenitor procapsid, three stable capsid species that can be isolated by differential sedimentation in continuous sucrose gradients are produced: A, B, and C capsids (9, 26, 58). The production of A capsids, which lack DNA and a scaffold, requires a functional terminase (1, 3, 44). A capsids are likely failed attempts at genome packaging (59, 70). B capsids are also nonproductive structures but, unlike A capsids, retain a proteolyzed scaffold, lack DNA, and can form independently of encapsidation (1, 3, 44, 57, 60, 71, 95). During successful packaging, the scaffolding is cleaved and replaced by the incoming genomic DNA, resulting in a C capsid (9, 58, 59).

The NEC consists primarily of two conserved viral proteins, pUL31 and pUL34 in herpes simplex virus (HSV) nomenclature, that are required for primary envelopment in all herpesviruses studied (25, 40, 45, 47, 93). pUL34 is a type II transmembrane protein (63, 69) that localizes to the endoplasmic reticulum (ER) and the nuclear membrane in transfected cells (66, 75). Upon coexpression, pUL31 and pUL34 are retained within the inner nuclear membrane, which reflects the normal distribution of the proteins during infection (25, 66, 67, 91). Therefore, each of these proteins requires the presence of the other for their proper localization to the nuclear membrane. Although pUL31 and pUL34 do not have known enzymatic activities, their coexpression can produce budding events at the inner nuclear membrane (34), and they are required for the budding of capsids into the perinuclear space in infected cells (20, 25, 27, 38, 49, 66, 69, 75). Perinuclear enveloped capsids are infrequently observed during infection with wild-type viruses and are thought to represent short-lived intermediates in the nuclear egress pathway that rapidly fuse with the outer nuclear membrane to deliver the capsid to the cytosol (28).

However, the NEC mechanism of action remains ambiguous, and alternative models of nuclear egress that do not involve capsid budding through the inner nuclear membrane have been proposed (37, 41, 79).

Part of the difficulty in identifying interactions between the NEC and capsids likely stems from the transience of the interactions during infection: although the NEC interacts with capsids, the NEC also dissociates from capsids following egress.
to the cytosol (25, 67). We considered that the blocking of nuclear egress may stabilize an NEC-capsid interaction and allow its identification. To this end, we present one strategy that proved successful: by deleting the UL34 gene from pseudorabies virus (PRV), pUL31 accumulated at intranuclear puncta during late infection. We show that these puncta overlap with capsid assemblies and demonstrate that pUL31 is a capsid-binding protein that copurifies with capsids in the absence of pUL34 in a manner that is independent of the pUL6 portal protein, pUL25 minor capsid protein, and pUL33 terminase protein.

**MATERIALS AND METHODS**

**Cells.** Vero cells were used for live-cell imaging. Viruses were propagated in pig kidney epithelial (PK15) cells. A PK15 cell line stably expressing pUL34 was described (17). The UL34 stable cell line was further modified to stably express either the pUL6, pUL25, or pUL33 protein.

**The subcloning of UL34 into a GP expression vector.** To subclone UL34 into a plasmid vector, the R6K plasmid (conditional replication origin) was used to propagate UL34-null viruses, was previously described (17). The UL34-null viruses were selected with 500 μg/ml G418. Clones of each lineage were saved as either plasmids.

**Materials.** The UL31 ORF was subcloned into the pLPCX vector by digestion with BglII and was PCR amplified with primers described (17). To subclone UL31 into a GFP expression vector, the R6K plasmid was used to propagate UL34-null viruses, described (17). The subcloning of UL25 into pLPCX (Clontech) was previously described (17). The UL34-null viruses were selected with 500 μg/ml G418 and 1 mg/ml G9261. Clones of each lineage were saved as either plasmids.

**Plasmids.** To delete UL34 from a PRV deletion clone, pGS3406 by deleting the UL34 gene from pSEU6, resulting in the deletion of codons 2 to 509 (of 534 aa total). This deletion design was based on a previous study (17). The primers used to delete UL34 were 5'-AGGGAGGTCGTAGTCGCTGGAGACGCCAAACTGTTACATGGGCCGCTGCGCGCTGCTCTTCTTC-3' immediately following the initiation codon, resulting in the deletion of codons 2 to 534 (of 642 aa total). This deletion design was based on a previous study (17).

**Plasmids.** The UL31-myc mammalian expression plasmid was previously described (17). To subclone UL31 into a GFP expression vector, the pUL31 plasmid was used to propagate UL34-null viruses, described (17). The subcloning of UL31 into a pLPCX vector by digestion with BglII and EcoRI. UL31 was subcloned by an alternative strategy following R6K amplification with primers 5'-GGCGCGTGTAGACGTAGCGCGACTGGAAGCTGTTG-3' and 5'-AGATCTGTCATCCATATCACCACG and inserted upstream of the UL31 ORF.

**Plasmids.** To delete UL34 from a PRV deletion clone, pGS3406 by deleting the UL34 gene from pSEU6, resulting in the deletion of codons 2 to 509 (of 534 aa total). This deletion design was based on a previous study (17).

**Plasmids.** The UL31-myc mammalian expression plasmid was previously described (17). To subclone UL31 into a GFP expression vector, the pUL31 plasmid was used to propagate UL34-null viruses, described (17). The subcloning of UL31 into a pLPCX vector by digestion with BglII and EcoRI. UL31 was subcloned by an alternative strategy following R6K amplification with primers 5'-GGCGCGTGTAGACGTAGCGCGACTGGAAGCTGTTG-3' and 5'-AGATCTGTCATCCATATCACCACG and inserted upstream of the UL31 ORF.
lysis buffer (0.15 M NaCl, 0.01 M Tris-HCl [pH 7.2], 2 mM MgCl2, 1% NP-40) then washed once in phosphate-buffered saline before being lysed in 1% NP-40 at 18 h postinfection and pelleted at 1,000 g.

Infected cells were harvested infected at a multiplicity of infection (MOI) of 10. Infected cells were harvested. Vero cells were grown to confluence in 850-cm2 roller bottles and adapted from that described previously by Bucks et al. (10), with slight modifications. Vero cells were grown to confluence in 850-cm2 roller bottles and infected with either PRV-GS847 or PRV-GS2847 16 h follow-
ing transfection and imaged at 8 to 10 h postinfection.

**Transfection.** For transient-transfection experiments with GFP-pUL31, 250 ng of pGS2896 DNA and 5 μl of Lipofectamine 2000 (Invitrogen) were incubated together in 400 μl of Dulbecco’s modified Eagle’s medium (DMEM) for 20 min. The mixture was then added to Vero cells plated onto glass coverslips in a 6-well plate. Cells were infected with either PRV-GS847 or PRV-GS2847 16 h follow-
ing transfection and imaged at 8 to 10 h postinfection.

**Intracellular capsid isolation.** Capsids were isolated by using a protocol adapted from that described previously by Bucks et al. (10), with slight modifi-
cations. Vero cells were grown to confluence in 850-cm2 roller bottles and infected with a multiplicity of infection (MOI) of 10. Infected cells were harvested at 18 h postinfection and pelleted at 1,000 g for 10 min at 4°C. The cells were then washed once in phosphate-buffered saline before being lysed in 1% NP-40 lysis buffer (0.15 M NaCl, 0.01 M Tris-HCl [pH 7.2], 2 mM MgCl2, 1% NP-40) supple-
minted with 5 mM dithiothreitol and protease inhibitor cocktail (Sigma) for 30 min on ice. The nuclei were separated from cytoplasmic material by cen-
trifugation at 1,000 g for 10 min at 4°C and washed once in 1% NP-40 lysis buffer. Nuclear lysis was achieved by passage through 18-, 21-, and then 25-gauge needles. Following lysis, 100 U of DNase I (MP Biomedicals) was added to the sample, and the sample was incubated for 15 min at 37°C. Nuclear debris was removed by centrifugation at 3,000 g for 10 min at 4°C. The resulting supernatant was overlaid onto 35% sucrose dissolved in TNE (20 mM Tris [pH 7.6], 500 mM NaCl, 1 mM EDTA) and centrifuged at an SW41 rotor at 25,000 rpm for 1 h at 4°C. The supernatant was aspirated, and the pellet was resuspended in TNE and dispersed by sonication. Capsids were then transferred onto a 20 to 50% sucrose gradient made in TNE using a Gradient Master (Sorvall). The sample was then centrifuged for 1 h at 4°C for 25,000 rpm in an SW41 rotor. The gradients were fractionated into 18 fractions by using a Gradient Fractionator (BioComp Instruments). Total protein was precipitated by the addition of trichloroacetic acid (TCA) to a final concentration. Following a 1-h incubation on ice, samples were centrifuged for 10 min at 4°C. The supernatant was aspirated, and the pellet was resuspended in loading buffer (31.25 mM Tris [pH 6.8], 5% glycerol, 0.005% bromophenol blue, 1% SDS, 5% (β-mercaptoethanol) supplemented with 0.1 N NaOH.

**Coimmunoprecipitation and Western blotting.** HEK-293 cells transiently transfected with pGS2896 and pGS2896 were suspended in TEEN buffer (50 mM Tris [pH 7.4], 1 mM EDTA, 1 mM EGTA, 150 mM NaCl) and subjected to 10 l-1 pulses in a cup sonicator. The samples were then rested on ice for 1 h. Ten microliters of prewashed protein A/G agarose beads (EMD) was incubated with 1 μl of anti-GFP rabbit serum (Invitrogen) for 2 h at 4°C. After three washes in TEEN buffer, the loaded beads were added to each sample and incubated at 4°C. They were then washed five times and resuspended in 2× final sample buffer (10 mM Tris [pH 7.4], 150 mM NaCl, 1% Triton X-100, 10% glycerol, 1% β-mercaptoethanol).

For Western blot analysis, samples were boiled for 5 min and separated through SDS-polyacrylamide gels. After transfer onto a polyvinylidine fluoride membrane (Bio-Rad), the membranes were blocked in 5% milk diluted in phosphate-
buffered saline with 0.1% Tween. The membranes were then probed with either anti-myc antibody (clone 9E10; provided by the Northwestern Monoclonal Ant"

**RESULTS**

**GFP-pUL31 localizes to capsid assemblies in the absence of UL34.** If the nuclear egress complex binds capsids to facilitate their egress, the interaction must be transient, as neither pUL31 nor pUL34 is detected on cytosolic capsids or in virions (25, 38, 49, 67). We hypothesized that if pUL31 was a conditional capsid-binding protein, its interaction with capsids may be stabilized if nuclear egress was blocked. To achieve this, the UL34 open reading frame was deleted from a recombinant strain of PRV that encodes two fluorescent tags: mRFP1-VP26 (monomeric red fluorescent protein 1 fused to capsids) and GFP-pUL31. The virus was propagated on a cell line, PK15-UL34, that stably expresses pUL34.

In Vero cells infected with a virus encoding an intact UL34 allele, GFP-pUL31 was enriched at the nuclear membrane, consistent with previous findings (25, 66, 67). A significant proportion of pUL31 was also distributed diffusely throughout the nucleus, which, based on a previous study, may have been associated with the nuclear matrix (13). In contrast, GFP-pUL31 was not enriched at the nuclear membrane in the absence of pUL34 but instead was frequently distributed to intranuclear capsid assemblies (Fig. 1A). This relocalization was observed for 78% (n = 59) of cells in which capsid assemblies were present, with the GFP-pUL31 emissions typically being detected at the periphery of the capsid assemblies (Fig. 1B).

This result provided the first indication that pUL31 may be a conditional capsid-binding protein. Because PRV encoding the GFP-pUL31 fusion propagated poorly (Table 1), the co-localization of pUL31 and capsid assemblies in the absence of pUL34 was confirmed by using a virus encoding unmodified pUL31. In this experiment, Vero cells were first transfected with a plasmid encoding the GFP-pUL31 fusion. These cells emitted GFP fluorescence diffusely from the nucleus (not shown). The cells were then infected with an mRFP1-VP26 virus with either an intact or a deleted UL34 allele. In cells infected with PRV encoding pUL34, the GFP-pUL31 localization remained diffuse throughout the nucleus but was also enriched at the nuclear membrane. In the absence of pUL34, GFP-pUL31 enrichment at the nuclear membrane did not occur (Fig. 1C). In this paradigm, the background level of GFP fluorescence was much higher than that in cells infected with the GFP-pUL31-encoding virus, but nevertheless, GFP-pUL31 foci were observed at the periphery of capsid assemblies in the absence of pUL34, thus recapitulating the findings made with PRV encoding the GFP-UL31 allele (Fig. 1D).

**pUL31 enrichment on purified capsids.** To determine if pUL31 stably interacts with capsids, capsids were recovered from the nuclei of infected Vero cells and isolated by sedimentation through sucrose gradients. The viruses that were used for these experiments did not encode fluorescent tags but instead encoded a myc epitope on the N terminus of pUL31. We note that although the fusion of GFP to the N terminus of maric acid-H2O, chemiluminescence solution, the membranes were exposed to film. ImageJ was used to perform densitometry analysis. **Fluorescence microscopy.** Microscopy was performed with a Nikon Eclipse TE2000-U inverted wide-field microscope with a 60×, 1.4-numerical-aperture oil objective (Nikon) and a Cascade:650 camera (Photometrics). The images were acquired and analyzed with Metamorph software (Molecular Devices).
pUL31 resulted in a >100× reduction in PRV titers, the myc epitope fusion propagated to wild-type titers (Table 1). A derivative of this virus was also constructed, in which UL34 was deleted. Capsids were separated in a continuous 20 to 50% sucrose gradient by rate-zonal centrifugation. The entire gradient was separated into 18 0.58-ml fractions that were subsequently TCA precipitated and examined by Western blot analysis.

Three light-diffracting bands were observed in sucrose gradients following centrifugation for both viruses, consistent with previous reports of A, B, and C capsids isolated from cells infected with HSV-1 (Fig. 2) (for an example, see reference 57). Due to the close migration of A and B capsid bands from the PRV-Becker clone, these capsid species did not resolve well following fractionation. We therefore refer to capsids in fractions containing A and B capsids as A/B capsids in this report. In cells infected with PRV encoding pUL34, myc-pUL31 was present evenly throughout the gradient (Fig. 3). The presence of pUL31 across the gradient is reminiscent of terminase proteins and the VP16 tegument protein from HSV-1-infected cells (56, 94). The lack of enrichment of myc-pUL31 in PRV capsid-containing fractions indicated that its presence was not capsid specific. However, in the absence of pUL34, myc-pUL31 was enriched in A/B- and C-capsid-containing fractions. The distribution of VP16 was also probed in the pUL34-null/myc-pUL31 gradient, and no reactivity was observed, indicating that the enrichment of myc-pUL31 was not due to a nonspecific aggregation process (not shown). The specificity of the pUL31-capsid interaction was further confirmed by using PRV mutants that do not produce C capsids; in these instances, myc-pUL31 reactivity was specifically lost from the corresponding fractions, while it was retained in the A/B fractions (see below). These data indicate that the localization of GFP-pUL31 to nuclear capsid assemblies was likely due to a pUL31-capsid interaction.

**pUL31 association with the capsid protein pUL25.** We previously applied a genetic screen based on a library of PRV isolates that encode red fluorescent capsids and deletions of individual viral genes to identify a capsid-binding site for the pUL36 large tegument protein (17). Because the localization of pUL31 to capsid assemblies occurred only in the absence of pUL34, the use of the mutant library to identify the pUL31-capsid interaction first required the design of a pUL31 construct that was able to interact with capsids but not with pUL34. We utilized a previously reported sequence alignment of pUL31 orthologs that identified four highly conserved regions of pUL31, conserved region 1 (CR1) through CR4 (42). Each of the conserved regions was subcloned into GFP expression vectors. Unfortunately, none of the conserved-region constructs localized robustly to capsid assemblies (data not shown). We therefore instead took a targeted approach and ranked candidate capsid proteins based on their potential roles in recruiting pUL31. The minor capsid protein pUL25 was our top candidate because (i) pUL25 was identified as a pUL31-binding partner in a yeast two-hybrid screen (86); (ii) pUL25 is ranked candidate capsid proteins based on their potential roles in genome encapsidation (54).

To determine if pUL31 and pUL25 interact in mammalian cells, HEK-293 cells were transiently transfected with PRV

### Table 1. Viral titers

<table>
<thead>
<tr>
<th>Virus Description</th>
<th>Cell line used for propagation</th>
<th>Titer (PFU/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No tags (WT)</td>
<td>PK15</td>
<td>1.0 x 10^8</td>
</tr>
<tr>
<td>mRFP1-VP26</td>
<td>PK15-UL34</td>
<td>2.2 x 10^6</td>
</tr>
<tr>
<td>myc-UL31</td>
<td>PK15</td>
<td>5.5 x 10^6</td>
</tr>
<tr>
<td>myc-UL34</td>
<td>PK15-UL34</td>
<td>&lt;500</td>
</tr>
<tr>
<td>myc-UL25</td>
<td>PK15-UL34</td>
<td>&lt;500</td>
</tr>
<tr>
<td>myc-UL6</td>
<td>PK15-UL34</td>
<td>&lt;500</td>
</tr>
<tr>
<td>myc-UL33</td>
<td>PK15-UL34</td>
<td>&lt;500</td>
</tr>
</tbody>
</table>

*WT, wild type.
myc-pUL25 and GFP-pUL31 expression plasmids. myc-pUL25 coprecipitated GFP-pUL31 but not GFP (Fig. 4). This result provided support for the two-hybrid finding in yeast performed with varicella-zoster virus (VZV) proteins (86). Several different functions of pUL31 are ascribed to separate conserved regions of the protein (42, 61, 73). To determine if one of the four conserved regions was sufficient for the pUL25 interaction, we included the four conserved-region constructs in the coimmunoprecipitation experiments. GFP-CR3 coprecipitated myc-UL25 at levels comparable to those of full-length pUL31, while GFP-CR2 and GFP-CR4 also proved capable of coprecipitation with myc-UL31 at reduced levels (Fig. 4). We cannot currently discriminate if these results indicate the presence of multiple independent pUL25-binding sites in pUL31 or if the pUL25-pUL31 interaction is nonspecific. Nevertheless, a role for pUL25 in pUL31 recruitment to capsids was next examined.

pUL25 is not required for the association of pUL31 with capsids. Because the pUL31-capsid interaction is observed only in the absence of pUL34, a recombinant form of PRV that encodes the myc-pUL31 fusion and deletions of the UL25 and UL34 open reading frames was made. The mutant virus was propagated in complementing cells that stably expressed both pUL25 and pUL34. Stocks of the mutant virus were monitored for the reversion of each gene by measuring titers from cells that expressed pUL25 and pUL34 separately (Table 1). Intranuclear capsids were then isolated from noncomplementing cells, resolved through sucrose gradients, and analyzed by Western blotting for the association of myc-pUL31. As previously described for HSV-1 lacking pUL25, the ΔUL25 ΔUL34 virus did not produce stable C capsids (Fig. 2) (44). Although C capsids were observed for a PRV UL25-null mutant by transmission electron microscopy, others have also noted the absence of PRV C capsids following sedimentation through sucrose, consistent with the requirement for pUL25 for the production of stable C capsids (39; F. Homa, personal communication). Surprisingly, the pattern of myc-pUL31 fractionation in the absence of pUL25 and pUL34 was similar to that observed in the absence of pUL34 alone; myc-pUL31 was enriched in A/B-capsid-containing fractions for both viruses (Fig. 5). While the absolute values derived from densitometry analyses of the Western blots varied between experiments, the trend of increased levels of pUL31 in capside fractions remained consistent. Also of note, the absence of C capsids from

FIG. 2. Sedimentation of PRV capsids through sucrose. Intranuclear capsids recovered from cells infected with viruses encoding a myc-pUL31 fusion were separated on continuous 20 to 50% sucrose gradients. Three light-diffracting bands are visible for the viruses with either a wild-type UL34 allele or a UL34 deletion allele. Only A and B capsid bands are apparent in the absence of pUL25, and only B capsids are visible in the absence of either pUL6 or pUL33.

FIG. 3. Association of pUL31 with purified intranuclear capsids. Capsids were isolated from the nuclei of Vero cells infected with PRV encoding a myc-pUL31 fusion and either an intact UL34 allele (wild type) or a UL34 deletion allele (ΔUL34) and separated on a linear sucrose gradient by rate-zonal centrifugation. Western blots of gradient fractions probed for myc-pUL31 and VP5 are shown. Fractions are labeled 1 (top of the gradient) to 18 (bottom of the gradient). Densitometries of myc-pUL31 (solid lines) and VP5 (dashed lines) are presented in the bottom panels.
the ΔUL25 ΔUL34 infections was accompanied by the loss of pUL31 specifically from the corresponding fractions, providing further support that the presence of pUL31 in the gradients was specifically a result of the capsid association.

The capsid portal and pUL33 terminase protein are not required for the capsid-pUL31 interaction. Two additional proteins were tested for roles in pUL31 recruitment by making double mutant viruses and corresponding dual complementing cell lines: pUL6 and pUL33. In addition to interacting with pUL25, the VZV pUL31 ortholog interacts with the terminase protein pUL33 in a yeast two-hybrid paradigm. Unlike the finding for pUL25-pUL31, the pUL31-pUL33 interaction can be observed with orthologs from the alpha-, beta-, and gammaherpesvirinae subfamilies, and the formation of a murine cytomegalovirus (MCMV) M50-M53-M51 (pUL34-pUL31-pUL33) complex was observed previously in transfected mammalian cells (22, 86). Although pUL33 is not a capsid protein, it is a component of the terminase, which is associated with the capsid during genome encapsidation and copurifies with B capsids (7). The pUL6 portal protein was included for study because it is required for the production of C capsids and nuclear egress (23, 57).

PRV encoding myc-pUL31 and either the ΔUL6 ΔUL34 or ΔUL33 ΔUL34 alleles were propagated on PK15-derived cell lines that stably expressed pUL34 together with pUL6 or pUL33. The resulting virus stocks were confirmed for a lack of reversion by a plaque assay on cell lines that stably express one of the proteins missing from the virus (Table 1). Intranuclear capsids were purified from infected noncomplementing Vero cells. Following rate-zonal centrifugation, pUL31 was enriched in B-capsid-containing fractions for both double mutant viruses (Fig. 6). Collectively, these results indicate that pUL6 (portal), pUL25 (capsid surface component), and pUL33 (terminase), all of which are essential for capsid nuclear egress, are each independently dispensable for the recruitment of pUL31 to capsids in this paradigm.

**DISCUSSION**

Herpesvirus capsids are assembled and packaged in the nucleus. The herpesvirus capsid is 125 nm in diameter, which is on par with the external diameter of a nuclear pore. Therefore, herpesvirus capsids must egress from nuclei by a process not normally active in mammalian cells. Based foremost on electron microscopy data, the favored model of nuclear egress is by capsids budding into the nuclear envelope. Once capsids are in the cytosol, the final envelopment process is in part engaged by capsids interacting with tegument and envelope proteins. For HSV-1, some tegument proteins are associated with nuclear and perinuclear capsids, and viral glycoproteins are resident in the nuclear membranes (4–6, 10, 21, 48, 55, 64, 67). For PRV, few of the virion structural proteins are seen associated with the nuclear membrane or nuclear capsids (29, 33, 46). The core NEC proteins pUL31 and pUL34 are nonstructural viral proteins conserved across the herpesviridae (25, 38, 67). In the alphaherpesvirinae, the pUS3 kinase is one protein known to serve as an accessory NEC component (36, 67, 88).

Defining the NEC is complicated in that if the mutation or deletion of a gene does not cause a dramatic defect in nuclear egress, its role may go unnoticed. This is due in part to a heavy reliance on electron microscopy to study nuclear egress and the challenge in identifying small reductions in levels of cytosolic capsids by this method. While the deletion of UL31 or UL34 results in a dramatic reduction in nuclear egress, and the deletion of US3 results in easily observed accumulations of enveloped capsids between the inner and outer nuclear membranes, the role of other proteins in nuclear egress has been controversial. For example, we previously reported a partial defect in nuclear egress for PRV deleted for the UL36 gene using a fluorescence microscopy assay, while another study could not detect a nuclear egress defect with a UL36-null PRV based on electron microscopy (24, 43). We are currently preparing a manuscript describing additional data that substantiate a supporting role for UL36 in PRV nuclear egress, and it was this work that began our interest in a better understanding of NEC-capsid interactions.

The incorporation of pUL31 and pUL34 in primary enveloped capsids has led to a model that the nuclear egress complex interacts directly with capsids (61, 67). Although the VP5
major capsid protein coprecipitates with the NEC from infected cells, evidence supporting a direct link between the NEC and intact capsids has yet to be established (93). Furthermore, the observation that C capsids are enriched for nuclear egress suggests that the NEC selects for capsids containing genomes. The mechanism of C capsid selectivity is unknown and is particularly mysterious given that the genome internal to the C capsid must somehow engender a feature on the C capsid exterior that is recognized by the NEC. The pUL25 minor capsid protein, along with its binding partner pUL17, was proposed as a candidate C-capsid-specific component (CCSC) that may interact with the NEC (85). However, the CCSC was subsequently identified on A and B capsids, making it a less compelling candidate as a selectivity factor (82).

This study provides the first formal evidence that the NEC binds to capsids. Key to this finding was the requirement for the work to be carried out with a UL34-null virus, which is incapable of exporting C capsids from the nucleus. Under these circumstances, pUL31 remained competent to bind capsids, while the trigger for the dissociation of the NEC from

FIG. 5. pUL25 is not required for the association of pUL31 with capsids. Vero cells were infected with PRV encoding myc-UL31 and either ΔUL34 or ΔUL25/ΔUL34. Intranuclear capsids were processed and analyzed as described in the legend of Fig. 3. Densitometries of myc-pUL31 (solid lines) and VP5 (dashed lines) are presented in the bottom panels.

FIG. 6. pUL31 association with capsids in the absence of the pUL6 portal and UL33 terminase component. Vero cells were infected with PRV encoding myc-UL31 and either ΔUL6/ΔUL34 or ΔUL33/ΔUL34. Intranuclear capsids were processed and analyzed as described in the legend of Fig. 3. Densitometries of myc-pUL31 (solid lines) and VP5 (dashed lines) are presented in the bottom panels.
capsids upon deposition in the cytosol was absent. We expect that this allowed the accumulation of what normally would be a short-lived pUL31-capsid intermediate complex. The interaction of pUL31 with capsids was initially identified through fluorescence microscopy and was further confirmed by the purification of capsids from the nuclei of infected cells.

Interestingly, pUL31 was located at the periphery of capsid assemblies during infection with the UL34-null virus. This is different from the pattern of colocalization seen when the C-terminal capsid-binding domain of the VP1/2 tegument protein is overexpressed in infected cells, which is centered upon capsid assemblies (17). While the meaning of these differences is unknown to us, they do merit some consideration. In these studies, capsid assemblies were observed based on a fluorescent protein fusion to the VP26 hexon component of capsids. Because VP26 is absent from procapsids, the VP1/2 capsid-binding domain presumably decorates clusters composed of A, B, or C capsids (15, 53, 74). Procapsids, seen as large-core B capsids by transmission electron microscopy, and C capsids are often observed at the periphery of capsid crystalline arrays in the nucleus (1, 16, 30, 68). Because capsid crystalline arrays and VP26 fluorescent capsid assemblies are likely one and the same, the peripheral localization of pUL31 may indicate that the NEC has a propensity to interact with procapsids undergoing maturation to C capsids at sites that are likely replication compartments (62, 66, 76, 89). This model is consistent with previous findings that pUL31 participates in DNA encapsidation (14, 61).

We were initially surprised to observe pUL31 associated with not just C capsids but also A/B capsids. This finding puts an important constraint on models of C capsid egress selectivity: selection does not occur by restricting NEC binding to packaged capsids. Several putative binding partners for pUL31 were identified previously by two-hybrid analysis, most notably pUL25 and pUL33. The interaction between pUL33 and pUL31 was identified in all three subfamilies of the herpesviridae, while the pUL25-pUL31 interaction appeared to be unique to the alphaherpesvirinae (22, 86). Both pUL25 and pUL33 are attractive candidates for links between the NEC and capsids, as both are required for capsid nuclear egress and both are capsid-associated proteins (7, 35, 54). pUL25 is a nonintegral capsid component that contributes to a structure variously referred to as the CCSC for its enrichment on C capsids and, more recently, as the capsid vertex-specific component (CVSC), because the structure was also identified on A and B capsids and is consistently observed around the icosahedral vertices (82, 85). pUL33 is a component of the viral terminase and as such is transiently associated with the capsids during encapsidation (3, 7). Evidence supporting the pUL33 interaction with the NEC comes from the colocalization of the MCMV orthologs at the nuclear membrane following cotransfection (22). A confirmation of pUL25 as an authentic binding partner of pUL31 is currently lacking. Although PRV pUL25 coimmunoprecipitated with pUL31 from transfected cells in this study, making conclusions regarding the specificity of this interaction was difficult, given that multiple nonoverlapping fragments of pUL31 bound pUL25. Furthermore, pUL25 was dispensable for the recruitment of pUL31 to capsids, indicating that if the interaction between pUL25 and pUL31 is biologically relevant, it is at best redundant for the recruitment of pUL31 to capsids. Because pUL33 and pUL6 were also dispensable for the pUL31-capsid interaction, pUL31 binding to capsids likely occurs through another protein or by multiple redundant interactions. In the above-mentioned VZV yeast two-hybrid study, pUL31 interacted with several additional proteins of interest, including the minor capsid protein pUL17 and the inner tegument protein pUL36 (86). It is also possible that integral capsid proteins may provide pUL31-binding sites.

In support of the latter possibility, pUL31 communoprecipitates with several proteins from infected cells, including the major capsid protein VP5 (93).

With regard to the egress trigger, the finding that pUL25 functions in nuclear egress in addition to its role in C capsid stabilization has placed pUL25 at center stage in current models of egress (54). However, it may be of interest that one of the earliest-described roles of pUL31 is in DNA cleavage and encapsidation of HSV-1, and support for this concept was more recently obtained with MCMV (14, 61). Coupling between the NEC and encapsidation is a compelling candidate as a nuclear egress trigger that may work in conjunction with pUL25. Genome encapsidation triggers the cleavage of the pUL15 component of the terminase, and at least two of the terminase components dissociate from the capsid (70, 72, 74, 95). Therefore, there are several potential signals that may be relayed from the terminase to the NEC and provide for C capsid selective egress.

While the manuscript was under review, a related study using HSV-1 was published (92). Inconsistent with our study, those authors observed that pUL31 was enriched on capsids despite the presence of pUL34. Also inconsistent was that pUL31 recruitment to HSV-1 capsids was dependent on pUL25. Although those findings were interpreted as evidence of an interaction between the NEC and the CVSC, the pUL17 component of the CVSC was dispensable for the pUL31-capsid association. Another recent study reported that in the absence of pUL17, the entire CVSC density is lost from capsids (82). However, some pUL25 is known to remain on capsids in the absence of pUL17, and it may be that this residual pUL25 could account for the pUL31 recruitment reported for HSV-1 in the absence of the CVSC (80). This would also be consistent with their finding that the level of pUL31 binding to C capsids was lower than that to A and B capsids, which would not be predicted if pUL31 was recruited specifically by the CVSC structure. The absence of this particular relationship may serve as an indication that HSV-1 pUL31 interacts with capsids through an additional capsid-associated protein, which is consistent with our model.

ACKNOWLEDGMENTS
The monoclonal antibody directed against the myc epitope was provided by the Robert H. Lurie Comprehensive Cancer Center Monoclonal Antibody Facility at Northwestern University. The PRV VP5 and VP16 antibodies were a gift from Lynn Enquist. This work was funded by NIH grant R01 AI080658 to G.A.S.

REFERENCES
Granzow, H., et al.
Fuchs, W., B. G. Klupp, H. Granzow, N. Osterrieder, and T. C. Mettenleiter. 1995. The 25 amino acid residues at the carboxy terminus of the herpes simplex virus type 1 UL26.5 protein are required for the carboxy terminal of the capsid shell around the scaffold. J. Gen. Virol. 76:Pt. 7:1611–1621.


